Rein Therapeutics, Inc. (RNTX) stock
RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.04 (-10.90%)
Close on Nov 17, 2026Market cap $30.75MP/E –Yield 0.00%
Rein Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Rein Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.39M, down 27.8% year over year. For fiscal 2025 it was $11.03M, down 22.6% from the year before. Over ten years it grew 3.5% a year on average. The highest annual figure on record is $18.45M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.03M | -22.6% |
| FY2024 | Dec 31, 2024 | $14.25M | +257.0% |
| FY2023 | Dec 31, 2023 | $3.99M | -77.8% |
| FY2022 | Dec 31, 2022 | $17.97M | +5.6% |
| FY2021 | Dec 31, 2021 | $17.01M | +52.3% |
| FY2020 | Dec 31, 2020 | $11.17M | -36.8% |
| FY2019 | Dec 31, 2019 | $17.66M | -4.3% |
| FY2018 | Dec 31, 2018 | $18.45M | +29.6% |
| FY2017 | Dec 31, 2017 | $14.24M | +38.6% |
| FY2016 | Dec 31, 2016 | $10.28M | +31.2% |
| FY2015 | Dec 31, 2015 | $7.83M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.64M | -15.2% |
| Q1 FY2026 | Mar 31, 2026 | $3.07M | +0.6% |
| Q4 FY2025 | Dec 31, 2025 | $2.00M | -39.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.68M | -54.8% |
| Q2 FY2025 | Jun 30, 2025 | $4.29M | +14.7% |
| Q1 FY2025 | Mar 31, 2025 | $3.05M | -11.8% |
| Q4 FY2024 | Dec 31, 2024 | $3.32M | +68.5% |
| Q3 FY2024 | Sep 30, 2024 | $3.72M | +16818.2% |
| Q2 FY2024 | Jun 30, 2024 | $3.74M | +1900.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.46M | +91.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.97M | -17.9% |
| Q3 FY2023 | Sep 30, 2023 | $22.00K | -99.5% |
| Q2 FY2023 | Jun 30, 2023 | $187.00K | -96.6% |
| Q1 FY2023 | Mar 31, 2023 | $1.81M | -69.3% |
| Q4 FY2022 | Dec 31, 2022 | $2.40M | -47.3% |
| Q3 FY2022 | Sep 30, 2022 | $4.24M | -0.9% |
| Q2 FY2022 | Jun 30, 2022 | $5.43M | +41.0% |
| Q1 FY2022 | Mar 31, 2022 | $5.89M | +36.5% |
| Q4 FY2021 | Dec 31, 2021 | $4.56M | +136.9% |
| Q3 FY2021 | Sep 30, 2021 | $4.28M | +59.4% |
| Q2 FY2021 | Jun 30, 2021 | $3.85M | +54.9% |
| Q1 FY2021 | Mar 31, 2021 | $4.32M | +6.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.93M | -59.1% |
| Q3 FY2020 | Sep 30, 2020 | $2.68M | -40.0% |
| Q2 FY2020 | Jun 30, 2020 | $2.49M | -42.2% |
| Q1 FY2020 | Mar 31, 2020 | $4.07M | -2.5% |
| Q4 FY2019 | Dec 31, 2019 | $4.71M | +18.9% |
| Q3 FY2019 | Sep 30, 2019 | $4.48M | +3.6% |
| Q2 FY2019 | Jun 30, 2019 | $4.31M | -19.1% |
| Q1 FY2019 | Mar 31, 2019 | $4.17M | -13.9% |
| Q4 FY2018 | Dec 31, 2018 | $3.96M | -8.1% |
| Q3 FY2018 | Sep 30, 2018 | $4.32M | +13.0% |
| Q2 FY2018 | Jun 30, 2018 | $5.32M | +68.3% |
| Q1 FY2018 | Mar 31, 2018 | $4.85M | +64.7% |
| Q4 FY2017 | Dec 31, 2017 | $4.31M | +39.4% |
| Q3 FY2017 | Sep 30, 2017 | $3.83M | +46.8% |
| Q2 FY2017 | Jun 30, 2017 | $3.16M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.94M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.09M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.61M | – |
See a number that looks wrong?